Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03088605 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of TOP1630 for Dry Eye Syndrome
A Phase 2 study, sponsored by ORA.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
NCT03088605 is a Phase 2 study that has completed, run by ORA. The registered enrollment target is 69 participants.
The verdict
NCT03088605, a Phase 2 study, has completed, sponsored by ORA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
Study Summary
In subjects with Dry Eye Syndrome: The primary objective of this study is to compare the safety and tolerability of TOP1630 Ophthalmic Solution to placebo. The secondary objectives are to compare the efficacy of TOP1630 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye syndrome.
Interventions
- DRUG TOP1630 Ophthalmic Solution
- DRUG Placebo to TOP1630 Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2017-02-20 |
| Est. Completion | 2017-06-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03088605
The ClinicalTrials.gov registry entry for NCT03088605 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ORA, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TOP1630 Ophthalmic Solution is the first listed.
NCT03088605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03088605 about?
NCT03088605 is a clinical study titled "Safety and Efficacy of TOP1630 for Dry Eye Syndrome". In subjects with Dry Eye Syndrome: The primary objective of this study is to compare the safety and tolerability of TOP1630 Ophthalmic Solution to placebo. The secondary objectives are to compare the efficacy of TOP1630 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of ...
What is the current status of trial NCT03088605?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2017-02-20. Estimated completion is 2017-06-15.
What interventions are being tested in trial NCT03088605?
The interventions under investigation include: TOP1630 Ophthalmic Solution (DRUG), Placebo to TOP1630 Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT03088605?
This trial is sponsored by ORA, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.